These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 18474674)

  • 1. Squalenoylation favorably modifies the in vivo pharmacokinetics and biodistribution of gemcitabine in mice.
    Reddy LH; Khoury H; Paci A; Deroussent A; Ferreira H; Dubernet C; Declèves X; Besnard M; Chacun H; Lepêtre-Mouelhi S; Desmaële D; Rousseau B; Laugier C; Cintrat JC; Vassal G; Couvreur P
    Drug Metab Dispos; 2008 Aug; 36(8):1570-7. PubMed ID: 18474674
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A new nanomedicine of gemcitabine displays enhanced anticancer activity in sensitive and resistant leukemia types.
    Reddy LH; Dubernet C; Mouelhi SL; Marque PE; Desmaele D; Couvreur P
    J Control Release; 2007 Dec; 124(1-2):20-7. PubMed ID: 17878060
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Squalenoyl nanomedicine of gemcitabine is more potent after oral administration in leukemia-bearing rats: study of mechanisms.
    Reddy LH; Ferreira H; Dubernet C; Mouelhi SL; Desmaele D; Rousseau B; Couvreur P
    Anticancer Drugs; 2008 Nov; 19(10):999-1006. PubMed ID: 18827565
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The deaminated metabolite of gemcitabine, 2',2'-difluorodeoxyuridine, modulates the rate of gemcitabine transport and intracellular phosphorylation via deoxycytidine kinase.
    Hodge LS; Taub ME; Tracy TS
    Drug Metab Dispos; 2011 Nov; 39(11):2013-6. PubMed ID: 21832002
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gemcitabine-based therapy for pancreatic cancer using the squalenoyl nucleoside monophosphate nanoassemblies.
    Maksimenko A; Caron J; Mougin J; Desmaële D; Couvreur P
    Int J Pharm; 2015 Mar; 482(1-2):38-46. PubMed ID: 25448549
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interaction of an amphiphilic squalenoyl prodrug of gemcitabine with cellular membranes.
    Bildstein L; Pili B; Marsaud V; Wack S; Meneau F; Lepêtre-Mouelhi S; Desmaële D; Bourgaux C; Couvreur P; Dubernet C
    Eur J Pharm Biopharm; 2011 Nov; 79(3):612-20. PubMed ID: 21784150
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anticancer efficacy of squalenoyl gemcitabine nanomedicine on 60 human tumor cell panel and on experimental tumor.
    Reddy LH; Renoir JM; Marsaud V; Lepetre-Mouelhi S; Desmaële D; Couvreur P
    Mol Pharm; 2009; 6(5):1526-35. PubMed ID: 19634915
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extensive metabolism and hepatic accumulation of gemcitabine after multiple oral and intravenous administration in mice.
    Veltkamp SA; Pluim D; van Tellingen O; Beijnen JH; Schellens JH
    Drug Metab Dispos; 2008 Aug; 36(8):1606-15. PubMed ID: 18490432
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transmembrane diffusion of gemcitabine by a nanoparticulate squalenoyl prodrug: an original drug delivery pathway.
    Bildstein L; Dubernet C; Marsaud V; Chacun H; Nicolas V; Gueutin C; Sarasin A; Bénech H; Lepêtre-Mouelhi S; Desmaële D; Couvreur P
    J Control Release; 2010 Oct; 147(2):163-70. PubMed ID: 20691740
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Simultaneous determination of gemcitabine prodrug, gemcitabine and its major metabolite 2', 2'-difluorodeoxyuridine in rat plasma by UFLC-MS/MS.
    Sun Y; Zhen L; Peng Y; Wang J; Fei F; Aa L; Jiang W; Pei X; Lu L; Liu J; Wang G; Hao K
    J Chromatogr B Analyt Technol Biomed Life Sci; 2018 May; 1084():4-13. PubMed ID: 29558739
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Magnetoresponsive squalenoyl gemcitabine composite nanoparticles for cancer active targeting.
    Arias JL; Reddy LH; Couvreur P
    Langmuir; 2008 Jul; 24(14):7512-9. PubMed ID: 18540685
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Investigation of the pharmacokinetics of gemcitabine and 2',2'-difluorodeoxyuridine in human plasma by liquid chromatography.
    Yilmaz B; Kadioğlu YY; Aksoy Y
    Anal Biochem; 2004 Sep; 332(2):234-7. PubMed ID: 15325290
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intraperitoneal gemcitabine pharmacokinetics: a pilot and pharmacokinetic study in patients with advanced adenocarcinoma of the pancreas.
    Gamblin TC; Egorin MJ; Zuhowski EG; Lagattuta TF; Herscher LL; Russo A; Libutti SK; Alexander HR; Dedrick RL; Bartlett DL
    Cancer Chemother Pharmacol; 2008 Sep; 62(4):647-53. PubMed ID: 18040687
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New insights into the pharmacology and cytotoxicity of gemcitabine and 2',2'-difluorodeoxyuridine.
    Veltkamp SA; Pluim D; van Eijndhoven MA; Bolijn MJ; Ong FH; Govindarajan R; Unadkat JD; Beijnen JH; Schellens JH
    Mol Cancer Ther; 2008 Aug; 7(8):2415-25. PubMed ID: 18723487
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Simultaneous determination of gemcitabine and its main metabolite, dFdU, in plasma of patients with advanced non-small-cell lung cancer by high-performance liquid chromatography-tandem mass spectrometry.
    Marangon E; Sala F; Caffo O; Galligioni E; D'Incalci M; Zucchetti M
    J Mass Spectrom; 2008 Feb; 43(2):216-23. PubMed ID: 17941128
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modulation of gemcitabine (2',2'-difluoro-2'-deoxycytidine) pharmacokinetics, metabolism, and bioavailability in mice by 3,4,5,6-tetrahydrouridine.
    Beumer JH; Eiseman JL; Parise RA; Joseph E; Covey JM; Egorin MJ
    Clin Cancer Res; 2008 Jun; 14(11):3529-35. PubMed ID: 18519786
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Measurement of the anticancer agent gemcitabine and its deaminated metabolite at low concentrations in human plasma by liquid chromatography-mass spectrometry.
    Xu Y; Keith B; Grem JL
    J Chromatogr B Analyt Technol Biomed Life Sci; 2004 Apr; 802(2):263-70. PubMed ID: 15018786
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Simultaneous determination of gemcitabine and gemcitabine-squalene by liquid chromatography-tandem mass spectrometry in human plasma.
    Khoury H; Deroussent A; Reddy LH; Couvreur P; Vassal G; Paci A
    J Chromatogr B Analyt Technol Biomed Life Sci; 2007 Oct; 858(1-2):71-8. PubMed ID: 17851141
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro studies on the immunosuppressive effect of 2',2'-difluorodeoxycytidine (dFdC) and its metabolite 2',2'-difluorodeoxyuridine (dFdU).
    Tiefenthaler M; Hohla F; Irschick E; Strasser-Wozak E; Bacher N; Mühlmann O; Wein W; Konwalinka G
    Immunobiology; 2003; 207(2):149-57. PubMed ID: 12675273
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of gemcitabine and 2',2'-difluorodeoxyuridine in a patient with ascites.
    Delauter BJ; Ramanathan RK; Egorin MJ; Stover LL; Zuhowski EG; Plunkett W; Zamboni WC
    Pharmacotherapy; 2000 Oct; 20(10):1204-7. PubMed ID: 11034044
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.